© 2001 by European Society of Cardiology
Copyright © 2000, European Society of Cardiology
The renal urodilatin system: clinical implications
IPF PharmaCeuticals GmbH, An-Institute of Hannover Medical School, Feodor Lynen-Strasse 31, D–30 625 Hannover, Germany
* Corresponding author wgforssmann{at}gmx.de
A renal natriuretic peptide and the ‘renal urodilatin system’ were identified after the observation that immunoassayable ANP in urine may not be identical to the circulating cardiac hormone ANP, which is a peptide of 28 amino acids. Urodilatin (INN: Ularitide) is a natriuretic peptide isolated from human urine and belongs to the family of A-type natriuretic peptides. Urodilatin is differentially processed to a peptide of 32 amino acids from the same precursor as ANP. It is synthesized in kidney tubular cells and secreted luminally. After secretion from epithelial cells of the distal and/or connecting tubules, Urodilatin interacts downstream at distal segments of the nephron with luminally located receptors whereby it regulates Na+ and water reabsorption. Thus, the physiological function of the renal Urodilatin system can be described as a paracrine intrarenal regulator for Na+ and water homeostasis, considering Urodilatin as a real diuretic-natriuretic regulatory peptide. However, the regulation upon which the Urodilatin secretion depends is still not clear. Since Urodilatin has been discovered, a great number of pharmacological and clinical investigations have been carried out using Urodilatin as a drug for several indications. So far, clinical phase I and II studies for acute renal failure, congestive heart failure, and bronchial asthma have been performed.
KEYWORDS Antihypertensive/diuretic agents; Blood pressure; Heart failure; Hormones; Natriuretic peptide; Renal function; Vasoconstrition/dilation
1 Working at CardioPep Pharma GmbH.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. De Luca, A. Mebazaa, G. Filippatos, J. T. Parissis, M. Bohm, A. A. Voors, M. Nieminen, F. Zannad, A. Rhodes, A. El-Banayosy, et al. Overview of emerging pharmacologic agents for acute heart failure syndromes Eur J Heart Fail, February 1, 2008; 10(2): 201 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Leinders-Zufall, R. E. Cockerham, S. Michalakis, M. Biel, D. L. Garbers, R. R. Reed, F. Zufall, and S. D. Munger Contribution of the receptor guanylyl cyclase GC-D to chemosensory function in the olfactory epithelium PNAS, September 4, 2007; 104(36): 14507 - 14512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. deGoma, R. H. Vagelos, M. B. Fowler, and E. A. Ashley Emerging Therapies for the Management of Decompensated Heart Failure: From Bench to Bedside J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2397 - 2409. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Mitrovic, P. M. Seferovic, D. Simeunovic, A. D. Ristic, M. Miric, V. S. Moiseyev, Z. Kobalava, K. Nitsche, W.-G. Forssmann, H. Luss, et al. Haemodynamic and clinical effects of ularitide in decompensated heart failure Eur. Heart J., December 1, 2006; 27(23): 2823 - 2832. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. H. Chen, A. Cataliotti, J. A. Schirger, F. L. Martin, and J. C. Burnett Jr. Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2005; 288(5): R1093 - R1097. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Heringlake, C. Heide, L. Bahlmann, W. Eichler, H. Pagel, P. Schmucker, R. Wergeland, F. P. Armbruster, and S. Klaus Effects of tilting and volume loading on plasma levels and urinary excretion of relaxin, NT-pro-ANP, and NT-pro-BNP in male volunteers J Appl Physiol, July 1, 2004; 97(1): 173 - 179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. I. McFarlane, N. Winer, and J. R. Sowers Role of the Natriuretic Peptide System in Cardiorenal Protection Arch Intern Med, December 8, 2003; 163(22): 2696 - 2704. [Abstract] [Full Text] [PDF]
|
|